Ligand Pharmaceuticals’ topical skin infection gel Zelsuvmi is changing hands again—sort of.  | The combined company is ...

Cysteinyl leukotrienes (CysLTs) are potent bronchoconstrictors, playing pivotal roles in inflammatory diseases. These lipid mediators exert their effects by activating two G protein-coupled receptors, ...

Ligand Pharmaceuticals has struck a deal to combine its Pelthos Therapeutics unit with Channel Therapeutics in a bid to accelerate the commercialization of its Zelsuvmi treatment for molluscum ...

The ERBB receptors are a group of receptor tyrosine kinases (RTKs) involved in key cellular functions including cell growth and survival. What are the activation mechanisms particular to ERBBs?

Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs.

Mapping an antibody’s epitope, where it binds a target, can now be done in three dimensions, which optimizes the selection of application-specific antibodies.

Scott et al, Impact of Intracellular Proteins on μ-Opioid Receptor Structure and Ligand Binding, The Journal of Physical Chemistry B (2024). DOI: 10.1021/acs.jpcb.4c05214 ...

Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching ...